Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 3/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 3/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967450 | 0.87 | LPL (0.36) | SNCALPLLIPGKDM4CIRAK4 | |
| SCHEMBL15064475 | 0.81 | LTA4H (0.46) | SNCALPLLIPGCA1CA2 | |
| SCHEMBL19965243 | 0.78 | LPL (0.40) | SNCALPLLIPGIRAK4IDO1 | |
| SCHEMBL623833 | 0.74 | CA1 (0.54) | HIF1ASNCALPLLIPGCA1 | |
| SCHEMBL28483833 | 0.74 | LPL (0.39) | SNCALPLLIPGCA1CA2 | |
| SCHEMBL2959390 | 0.74 | KDM4C (0.39) | KDM4CLTA4HIDO1NPC1RAB9A | |
| SCHEMBL30016416 | 0.74 | FABP6 (0.42) | SNCALPLLIPGCA1CA2 | |
| SCHEMBL3132769 | 0.74 | FABP6 (0.42) | SNCALPLLIPGCA1CA2 | |
| SCHEMBL16655694 | 0.74 | LPL (0.39) | SNCALPLLIPGCA1CA2 | |
| SCHEMBL13201515 | 0.72 | DDAH1 (0.46) | HIF1ASNCALPLLIPGIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1973917-A2 | PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007079164-A2 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | HIF1A 3288/4885SNCA 3339/4885LPL 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.